Skip to content
10-Q

Quarterly Report

ANIXA BIOSCIENCES, INC. ANIX

0001493152-24-035335

← back to feed
Filed
Sep 6, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Sep 6, 2024 32.18M sh
Short Term Investments Q3 2024 · Jul 31, 2024 $19.52M
Short Term Investments Q3 2024 · Oct 31, 2023 $22.93M
Cash And Equivalents Q3 2024 · Jul 31, 2024 $1.23M
Cash And Equivalents Q3 2024 · Oct 31, 2023 $915K
Stockholders Equity Q3 2024 · Jul 31, 2024 $21.77M
Stockholders Equity Q3 2024 · Oct 31, 2023 $24.34M
Current Liabilities Q3 2024 · Jul 31, 2024 $2M
Current Liabilities Q3 2024 · Oct 31, 2023 $2.03M
Total Liabilities Q3 2024 · Jul 31, 2024 $2.22M
Total Liabilities Q3 2024 · Oct 31, 2023 $2.15M
Current Assets Q3 2024 · Jul 31, 2024 $22.67M
Current Assets Q3 2024 · Oct 31, 2023 $25.36M
Total Assets Q3 2024 · Jul 31, 2024 $22.91M
Total Assets Q3 2024 · Oct 31, 2023 $25.52M
Shares Diluted Q3 2024 · Jul 31, 2023 30.97K sh
Shares Diluted Q3 2024 · Jul 31, 2023 30.94K sh
Operating Cash Flow Q3 2024 · Jul 31, 2023 −$4.24M
Eps Diluted Q3 2024 · Jul 31, 2023 −$0.08
Eps Diluted Q3 2024 · Jul 31, 2023 −$0.23
Eps Basic Q3 2024 · Jul 31, 2023 −$0.08
Eps Basic Q3 2024 · Jul 31, 2023 −$0.23
Rd Expense Q3 2024 · Jul 31, 2023 $1.09M
Rd Expense Q3 2024 · Jul 31, 2023 $3.15M
Net Income Q3 2024 · Jul 31, 2023 −$2.51M
Net Income Q3 2024 · Jul 31, 2023 −$7.12M
Operating Income Q3 2024 · Jul 31, 2023 −$2.84M
Operating Income Q3 2024 · Jul 31, 2023 −$7.96M
Revenue Q3 2024 · Jul 31, 2023 $210K